source
- Johnson & Johnson’s depression drug JNJ-5120 fails primary endpoint in phase 2 trialA phase 2 study of JNJ-5120, an M1 receptor antagonist developed by Johnson & Johnson with Contineum Therapeutics, did not meet its primary efficacy endpoint in patients with major depressive disor…
- Medtronic and Given Imaging recall Bravo CF esophageal pH monitoring capsule delivery devicesMedtronic and its subsidiary Given Imaging have issued a recall of the Bravo CF esophageal pH monitoring capsule delivery devices after reports that the capsules may fail to attach or detach from t…